ADVENTRX Pharmaceuticals Provides Update on ANX-514

ADVENTRX Pharmaceuticals, Inc. ANX today provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel. The U.S. Food and Drug Administration (FDA) determined that ANX-514 could not be approved based on the findings from the bioequivalence study of ANX-514 (Study 514-01) and that additional development activities would be required for approval. ADVENTRX met with the FDA to discuss required activities.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!